10/19/2005 5:11:48 PM
Lynx Therapeutics, Inc. (NASDAQ:LYNX) today announced the National Science Foundation (NSF) has awarded a research grant to the University of Delaware to utilize Lynx's Massively Parallel Signature Sequencing (MPSS(TM)) technology to develop methods to capture and sequence small (21 to 24 ribonucleotides) RNAs on a larger scale than previously possible. This new application will allow researchers to simultaneously discover novel small RNAs and quantify their expression patterns. These non-coding RNAs are primarily involved in degradation of messenger RNAs, but also function in the inhibition of translation and direct silencing of genes via the methylation of genomic DNA. Recent advances in silencing RNA have illustrated important biological roles for siRNAs and miRNAs. This contract will allow Lynx to further develop methods aimed at enhancing understanding of the regulation of transcription and translation in many higher organisms.
comments powered by